Track Record
Selected Transactions
A selection of principal investments, listed-company transactions and advisory mandates. Specific financial details, counterparty names and transaction terms are disclosed only to qualified counterparties under appropriate confidentiality arrangements.
London Listed Transactions
London
Principal participation and strategic advisory across a series of listed-company transactions involving the London Stock Exchange and AIM, including acquisition platforms, recapitalisations, equity placements and strategic block trades.
Strategic Adviser to London-Listed Acquisition Companies
London
Severn Capital has advised, and has been appointed as Strategic Adviser to, London-listed acquisition companies seeking suitable targets, transaction structures and capital-market pathways.
Ikigai Ventures / Dotlines Global
UK / Southeast Asia
Leadership role in the repositioning of London Stock Exchange listed Ikigai Ventures Limited (LON:IKIV) and the admission of Dotlines Global Limited (LON:DOTL) to AIM at a market capitalisation of c. £57.9 million, creating a UK and Southeast Asia focused technology platform spanning digital infrastructure, telecoms, cybersecurity and fintech.
Nova Satra Dx / INEX Innovate
Singapore
Co-founder of Nova Satra Dx, a Singapore-based molecular diagnostics business backed by Genting Berhad. In 2019, Nova Satra Dx merged with INEX Innovations Exchange in a US$72 million transaction to create INEX Innovate, backed by institutional investors including Genting Berhad and Enterprise Singapore.
iGene Laboratory
Singapore / Indonesia
Strategic involvement with iGene Laboratory, a Singapore MOH-licensed and CAP-accredited next generation sequencing laboratory, and PT iGene Laboratory Indonesia, a joint venture with Indonesia Stock Exchange-listed PT Itama Ranoraya Tbk (IDX:IRRA).
Asia / UK Cross-Border
Singapore · Hong Kong · London
Capital introductions, co-investment discussions and strategic transaction support between Singapore, Hong Kong, London and selected international counterparties.
The above represents a selection of transactions and advisory mandates. Not all transactions are listed. Specific financial details, counterparty names and transaction terms are confidential and disclosed only to qualified counterparties under appropriate non-disclosure arrangements. Past activity is not indicative of future results.